CTLA-4, ICOS, PD1 and PTPN22 Gene Polymorphisms and Susceptibility to Autoimmune Hepatitis Type 1
International Journal of Immunology
Volume 5, Issue 4, August 2017, Pages: 66-73
Received: Jun. 30, 2017; Accepted: Jul. 10, 2017; Published: Aug. 10, 2017
Views 2126      Downloads 109
Authors
María Del Pilar Fortes, Genetic Immunology Section, Immunology Institute/Universidad Central de Venezuela, Caracas, Venezuela
Paolo Tassinari, Genetic Immunology Section, Immunology Institute/Universidad Central de Venezuela, Caracas, Venezuela
Irma Machado, Genetic Immunology Section, Immunology Institute/Universidad Central de Venezuela, Caracas, Venezuela
Article Tools
Follow on us
Abstract
Autoimmune hepatitis type 1 (AIH-1) is a progressive inflammatory liver disorder in which HLA Class II gene polymorphism prevails as the most important genetic risk. However, other gene polymorphisms have been associated with this disease. The single nucleotide polymorphisms of four candidate genes (CTLA-4 +49A/G, ICOS c.1564 T/C, PD1.3 G/A, PTPN22 1858C/T) were selected in this study. One-hundred and ninety (190) mestizo Venezuelan unrelated individuals grouped in AIH-1 patients (n=70) and healthy subjects (n=120) were evaluated. Our results showed significantly increased frequency of the PTPN22 1858 C/T (p= 0.0014; pc= 0.0042; OR= 8.7; 99%CI: 1.82-41.54) and ICOS c.1564 T/C (p= 0.070; pc=0.21; OR= 2.08; 95%CI: 1.09-3.93) genotypes in the patient population compared to control group. There was no significant association between CTLA-4 +49A/G and PD1.3 G/A genotypes in both groups. In addition, the PTPN22 1858C/T polymorphism was associated to cirrhosis, treatment relapse, increased IgG levels and co-existence of other autoimmune diseases. Furthermore, the ICOS c.1564 T/C polymorphism was related to higher levels of globulins, IgG and presence of ANA. Conclusion: this data suggest for the first time, that PTPN22 1858 C/T and ICOS c.1564 T/C gene polymorphisms are associated with the development of AIH-1.
Keywords
Autoimmune Hepatitis Type 1, Mestizo Venezuelan, Genetics, Immunopathology, T Lymphocyte
To cite this article
María Del Pilar Fortes, Paolo Tassinari, Irma Machado, CTLA-4, ICOS, PD1 and PTPN22 Gene Polymorphisms and Susceptibility to Autoimmune Hepatitis Type 1, International Journal of Immunology. Vol. 5, No. 4, 2017, pp. 66-73. doi: 10.11648/j.iji.20170504.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174:250-9.
[2]
Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992; 67:1447-53.
[3]
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type I autoimmune hepatitis. Clin Liver Dis 2002; 6:707-25.
[4]
Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HLA-A1. Lancet 1972; 300:793-5.
[5]
Fortes MP, Machado IV, Gil GC, Fernández-Mestre M, Dagher L, León R, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver Intern 2007; 27: 1409-16.
[6]
G. J. Webb, G. M. Hirschfield. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimm 2016; 66:25-39.
[7]
Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Ríos M, Martínez M, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA-4 polymorphisms in multiple ethnic groups. Hum Mol Gen 1997; 6:1275-82.
[8]
Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1autoimmune hepatitis. Hepatology 2000; 31: 49-53.
[9]
Bittencourt PL, Palacios SA, Cancado EL, Porta G, Carrilho FJ, Laudanna AA, et al. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am J Gastroenterol 2003; 98 (7):1616-20.
[10]
Umemura T, Ota M, Yoshizawa K, Katsuyama Y, Ichijo T, Tanaka E, et al. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatol Res 2008; 38:689-95.
[11]
Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001; 62: 1356-62.
[12]
Fan LY, Tu XQ, Cheng QB, Zhu Y, Feltens R, Pfeiffer T, et al. Cytotoxic T lymphocyte associated antigen-4 gene polymorphisms confer susceptibility to primary biliary cirrhosis and autoimmune hepatitis in Chinese population. World J Gastroenterol 2004; 10:3056-3059.
[13]
Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, OstermanA, et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 117:699–711.
[14]
Mustelin T, Alonso A, Bottini N, Huynh H, Rahmouni S, NikaK, et al. Protein tyrosine phosphatases in T cell physiology. Mol Immunol 2004; 41:687–700.
[15]
Andersen JN, Jansen PG, Echwald SM, Mortensen OH, FukadaT, del Vecchio R, et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 2004; 18:8–30.
[16]
Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, lyp. Blood 1999; 93:2013–24.
[17]
Bottini N, Musumci L, Alonso A, Ralumouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337-8.
[18]
Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot Ma, Torres B, Caliz R, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005; 52:219-24.
[19]
Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75 (3):504-7.
[20]
Daniela Josabeth López-Cano, Daniel Cadena-Sandoval, Olga Beltrán-Ramírez, Rosa Elda Barbosa-Cobos, Fausto Sánchez-Muñoz, Luis Manuel Amezcua-Guerra, et al. The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population. Inflamm Res 2017:1-7.
[21]
Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 89 (11):5862-5.
[22]
Nishimura H, Honjo T. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 265–8.
[23]
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med2000; 192: 1027–34.
[24]
Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N, Azuma M, et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 2007; 57 (8):485-92.
[25]
Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, Kurihara C, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am J Gastroenterol 2007; 102 (2):302-12.
[26]
Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 1997; 197:177-87.
[27]
Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32:666-9.
[28]
Velázquez-Cruz R, Orozco L, Espinosa-Rosales F, Carreño-Manjarrez R, Solís-Vallejo E, López-Lara ND, et al. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet 2007; 15 (3):336-41.
[29]
Jie Gao, Nan Gai, Li Wang, Kang Liu, Xing-Han Liu, Lin-Ting Wei, et al. Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk. Oncotarget 2017; 8 (22): 36885-97.
[30]
Ferreiros-Vidal I, Gomez-Reino J, Barros F, Carracedo A, Carreira P, Gonzáles-Escribano F. Association of PDCD1 with susceptibility to systemic lupus erythematosus. Arthritis Rheumat 2004; 50 (8):2590-7.
[31]
Prokunina L, Padyukov L, Bennet A, de Faire U, Wiman B, Prince J, et al. Association of the PD-1 A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor the shared epitope. Arthritis Rheum 2004; 50 (6):1770-3.
[32]
Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type I diabetes. Tissue Antigens 2003; 62 (6):492-7.
[33]
Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH, et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 2006; 8 (6): R163.
[34]
Mahdi Mahmoudi, Alireza Rezaiemanesh, Arash Salmaninejad, Sara Harsini, Shiva Poursani, Tayyeb Bahrami et al. PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus. Autoimmunity 2015; 48 (7):488-93.
[35]
Hulfoff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-266.
[36]
Salomon B, Bluestone JA. Complexities of CD28/27: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann Rev Immunol 2001; 19:225-252.
[37]
Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409:97-101.
[38]
Aoki N, Kido M, Iwamoto S, Nishiura H. Dysregulated Generation of Follicular Helper T Cells in the Spleen Triggers Fatal Autoimmune Hepatitis in Mice. Gastroenterology 2011; 140:1322-1333.
[39]
María del Pilar Fortes, Gisselle Gill, María Elena Paredes, Ligia E. Gámez, Marina Palacios, Isaac Blanca, et al. Allele and haplotype frequencies at Human leukocyte antigen class I and II genes in Venezuela's population. Annales de Biologie Clinique 2012; 70 (2):175-81.
[40]
Alvarez E, Berg IA, Bianchi EB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31 (5):929-38.
[41]
Kouki T, Sawai Y, Gardine C, Fisfalen M, Alegre M, De Groot LJ. CTLA-4 Gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis de Grave´s disease. J Immunol 2000; 165 (11):6606-11.
[42]
Shangera DK, Manzi S, Bontempo F, Nestlerode C, Kamboh MI. Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies. Hum Genet 2004; 115 (5): 393–98.
[43]
Haimila KE, Partanen JA, Holopainen PM. Genetic polymorphism of the human ICOS gene. Immunogenetics 002; 53 (12):1028-32.
[44]
Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994; 43:18-27.
[45]
Daniel, W. Bioestadística. Base para el Análisis de las Ciencias de la Salud. Editorial Limusa-Wiley. 4ta edición. México, 2002:228-55.
[46]
Hammer, Ø., Harper, D. A. T., and P. D. Ryan. PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontología Electrónica 2001; 4 (1): 9pp. http://palaeo-electronica.org/2001_1/past/issue1_01. htm.
[47]
Bottini N, Vang T, Cucca F and Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006; 18:207-13.
[48]
Vang T, Congia M, Macis MD, Musumeci L, OrruV, Zavattari P, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2004; 303:685-9.
[49]
Brand O, Gough S, Heward J. HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? Expert rev 2005; 7 (23):1-15.
[50]
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-10.
[51]
Kaartinen T, Lappalainen J, Haimila K, Autero M, Partanen J. Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA-4. Mol Immunol 2007; 44:1644-1651.
[52]
Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery pregnancy in autoimmune hepatitis. Am J Gastroenterol 2002; 97:3160-3165.
[53]
Malhotra B, Malhotra N, Deka D, Takkar D. Immunosuppressive effect of pregnancy on autoimmune hepatitis: a case report and review of literature. Eur J Obstet Gynecol Reprod Biol. 2002; 101:91-92.
[54]
Sykes L, MacIntyre D, Yap X, Teoh T, Bennett P. The Th1: Th2 Dichotomy of Pregnancy and Preterm Labour. Mediators Inflamm 2012; 9:67-69.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186